All In Biotech

Drug Trial Radar · NCT04704999

Southeast Asia Dose Optimization of Tafenoquine

Optimizing the Dose of Tafenoquine for the Radical Cure of Plasmodium Vivax Malaria in Southeast Asia

Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 820 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

820

Planned (sponsor's estimate)

Start

Jul 22, 2024

Primary completion

Oct 4, 2027

Study completion Feb 7, 2028

Sponsor

Lead sponsor
University of OxfordAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Tafenoquine was recently approved by regulatory authorities in the USA and Australia. Tafenoquine is an alternative radical curative treatment to primaquine acting against the dormant liver stage of Plasmodium vivax (the hypnozoite). Tafenoquine (an 8-aminoquinoline) has the substantial advantage of single dosing as compared to a 14-day course of primaquine to achieve radical cure. The recommended tafenoquine dose is 300 mg, which was shown to be significantly worse in radical curative efficacy to a total primaquine dose of 3.5 mg/kg in Southeast Asia. The cure rate of tafenoquine 300 mg in Southeast Asian study sites was only 74%. The comparator 3.5 mg/kg total primaquine dose is the standard and most commonly used dose globally, but in Southeast Asia and the Western Pacific, higher doses of primaquine are needed for radical cure. This study aims to determine the optimal dose of tafenoquine in Southeast Asia. Addendum for Indonesia: The INSPECTOR trial results showed that tafenoquine 300mg was not efficacious for radical cure (79% probability for recurrence after treatment). The comparator arm, low-dose primaquine 3.5mg/kg divided equally over 14 days, showed a 48% probability of recurrence after treatment). The standard of care for radical cure in Indonesia is high-dose primaquine 7mg/kg divided in 7 daily doses).

Conditions

  • Plasmodium Vivax Malaria

Interventions

  • TafenoquineDrug

    Tafenoquine will be given as 100mg coated tablets. Tablets will be given based on weight bands.

  • ChloroquineDrug

    Chloroquine will be given as daily dose over 3 days (25mg/kg total dose divided 10/10/5mg/kg)

  • Artemether 20 mg-Lumefantrine 120 mgDrug

    Artemether-lumefantrine will be given twice daily over 3 days. Whole tablets will be given based on weight bands.

  • PrimaquineDrug

    Primaquine will be given once daily over 7 days (7mg/kg total dose divided 1mg/kg/day) as per the national malaria guidelines.

  • Dihydroartemisinin 40 mg-Piperaquine 320 mgDrug

    Dihydroartemisinin-piperaquine will be given once daily over 3 days. Whole tablets will be given based on weight bands.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Microscopy positive P. vivax recurrence after radical treatment up to month 4Time frame: At month 4

Locations

6 sites in 5 countries. Site status is shown where the registry gives one.

  • Mahidol Oxford Tropical Medicine Research Unit (MORU), Cambodia

    Siem Reap, Cambodia · Recruiting

  • Oxford University Clinical Research Unit (OUCRU-Indonesia)

    Jayapura, Indonesia · Not yet recruiting

  • Lao Oxford Mahosot Hospital Wellcome Trust Research Unit (LOMWRU)

    Vientiane, Laos · Recruiting

  • Mahidol Vivax Research Unit (MVRU)

    Bangkok, Thailand · Recruiting

  • Shoklo Malaria Research Unit (SMRU)

    Bangkok, Thailand · Recruiting

  • Oxford University Clinical Research Unit (OUCRU)

    Bình Phước, Vietnam · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.